San Diego, CA, United States of America

Kristin Taylor

USPTO Granted Patents = 15 


 

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 90(Granted Patents)


Company Filing History:


Years Active: 2012-2024

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: Kristin Taylor: Innovator in Cardiovascular Health

Introduction

Kristin Taylor is a prominent inventor based in San Diego, CA, who has made significant contributions to the field of cardiovascular health. With a total of 15 patents, her work focuses on innovative compositions and methods aimed at reducing major adverse cardiovascular events.

Latest Patents

Among her latest patents, Kristin has developed compositions and methods for reducing major adverse cardiovascular events. This application relates to the use of naltrexone and bupropion, or their pharmaceutically acceptable salts, to mitigate the risk of adverse cardiovascular outcomes, particularly in individuals who may be overweight or obese. Additionally, she has disclosed methods for treating overweight and obesity using naltrexone plus bupropion, ideally in conjunction with a comprehensive weight management program, targeting subjects at increased risk of adverse cardiovascular outcomes.

Career Highlights

Throughout her career, Kristin has worked with notable companies such as Nalpropion Pharmaceuticals LLC and Amylin Pharmaceuticals, Inc. Her innovative approaches have positioned her as a leader in the development of therapeutic solutions for cardiovascular health.

Collaborations

Kristin has collaborated with esteemed colleagues, including Preston Klassen and Mark S. Fineman, to further advance her research and innovations in the field.

Conclusion

Kristin Taylor's contributions to cardiovascular health through her patents and collaborations highlight her dedication to improving patient outcomes. Her innovative work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…